Patient safety

Management of the material topic (GRI 3-3)

Medication errors or quality issues with medications can have serious consequences for the health of patients. At the same time, they also pose a reputational risk for the companies involved. Digitalisation offers new opportunities for innovative solutions to improve patient safety. Galenica is committed to ensuring the quality of medicines along its entire value chain and takes the appropriate measures along the supply chain in terms of infrastructure, processes, and employee training and education. This helps prevent medication errors, reduce side effects and lower healthcare costs. With personal and competent advice and a unique range of products and services, Galenica supports its patients in all life situations and helps to enable people of all ages to lead a healthy life. Galenica thus makes an important contribution to the well-being and health of the Swiss population.

GDP guidelines for a good distribution practice

Alloga, Galexis, UFD, Pharmapool, Verfora and the Bichsel Group adhere to the GDP (Good Distribution Practice) guidelines for human medicinal products in an exemplary manner. On the one hand, these legal requirements are intended to prevent counterfeit drugs from entering legal supply chains. On the other hand, control measures within the distribution chain ensure the quality and integrity of medicines. Drug temperature is recorded and analysed in real time throughout the entire life cycle, from production through to delivery. If there are deviations in temperature, the causes are investigated and suitable measures are taken in accordance with GDP guidelines. In addition to these guidelines, the aforementioned companies apply their own standards and processes in their day-to-day work to ensure patient safety at all times.

Galexis, UFD, Pharmapool and the Bichsel Group each operate their own fleet comprising 178 delivery vans (up to 3.5 tonnes) and 5 lorries (14 to 22 tonnes). All vehicles are GDP-compliant and are fitted with an air conditioning system in the loading space, which is mandatory for the transport of pharmaceutical products.

Uninterrupted cold chain for medicines

All Wholesale & Logistics companies, as well as Medifilm, Mediservice and Bichsel, provide an uninterrupted cold chain for the storage and transport of temperature-sensitive medicines. At Alloga, this also applies to so-called ultra-deep-freeze logistics, in other words, storage and dispatch at –80°C, the required temperature for a new generation of cancer drugs. Temperature control is ensured by using dry ice in special containers. Alloga and Galexis also use paraffin-filled cooling elements, which, in contrast to water-based cooling elements, ensure a more stable temperature for the medicines.

Quality systems

HCI Solutions provides master data for the Swiss healthcare market. The company is also active in the area of e-health with the aim of increasing patient and medication safety in the Swiss healthcare system. With innovative digital solutions such as Documedis^®, HCI Solutions makes a significant contribution to safe and efficient healthcare in Switzerland. To guarantee the quality of medication data, HCI Solutions carries out process-integrated checks. The company verifies the recording of pharmaceutical data according to the four-eyes principle, while the six-eyes principle applies to sensitive active substances (such as blood thinners). HCI Solutions conducts random quality checks on a daily basis and a more comprehensive inspection every two weeks. Any error discovered is documented and its cause investigated. HCI Solutions is certified to ISO 9001:2015 and ISO 13485:2016.

The quality management system (QMS) of the Pharmacies has standard operating procedures (SOPs) for all relevant pharmacy processes. These include the manufacturing and dispensing of drugs, data protection, confidentiality, hygiene and the disposal of medicines. Compliance with SOPs in the individual pharmacies is regularly checked. In addition to these announced audits, anonymous test purchases and phone calls and inspections by cantonal pharmacists take place in all pharmacies. Several times a year, Galenica conducts QMS and legal requirements courses for pharmacy employees. Employees complete certified courses and obtain certificates of competence for specific healthcare services including various checks and vaccinations.

As a company specialising in pharmaceutical manufacturing and home care with its own certified general pharmacist, the Bichsel Group places great importance on the quality of its products and services. The company carries out numerous chemical and microbiological analyses on a daily basis to check end products, raw materials and packaging materials and holds manufacturing licenses, EU GMP certificates for medicinal products and EC certificates for medical devices in accordance with Directive 93/42/EEC of the European Council.

Further information on certifications and quality systems can be found in the section Sustainable and ethical corporate governance.

Continuous monitoring of all products

Product safety is checked and safeguarded at Verfora using a variety of approaches. Verfora checks the qualification of contract manufacturers through initial and regularly recurring audits, whereby compliance with the GMP guidelines is assessed and must be adhered to so that safe products can be manufactured for patients at all times. The audits also take into account environmental, health and safety factors within the partner companies. The products are then carefully examined before being placed on the market to ensure that they have been manufactured and tested in accordance with the GMP guidelines and that they meet all applicable specifications. As with all medications, Verfora products undergo preclinical and clinical trial to ensure their safety and efficacy. Once the products are on the market, pharmacovigilance is at the heart of Verfora’s safety efforts, i.e. the continuous monitoring of all products. All new Verfora employees are trained in pharmacovigilance and receive a checklist of steps to be taken in the event of side effects. In addition, pharmacovigilance training is held for all employees every year. The company also systematically checks advertisements and advertising posters for products to ensure they are correct. In parallel with pharmacovigilance, the products are regularly analysed in the laboratory until the end of their shelf life so that any deviations in quality can be identified and remedied at an early stage.

Promoting the technical competence of employees

In 2024, 101 pharmacists successfully completed the quality management course. Quality management and patient safety are also key issues in the basic training of pharmacy assistants working towards their Federal Proficiency Certificate.

Where required, Verfora offers training sessions for pharmacies when new medications are launched in order to promote employees’ skills and ensure patient safety and health. In 2024, Verfora conducted 126 training sessions for around 11,000 pharmacy assistants and pharmacists.

Increased patient safety using e-medication solution

Digitalisation is leading to new, innovative ways to improve patient safety. Documedis^® is a process-integrated solution for increased medication and patient safety in the healthcare system. Documedis^® offers specific e-health applications and services relating to the medication process based on INDEX data. Documedis^® has already been implemented in pharmacy, medical and hospital software.

Documedis^® includes clinical decision support checks (CDS.CE). These checks enable health specialists from medical practices, hospitals, pharmacies, home care organisations and care homes to check the patient’s used or planned medication for known risks, duplication or allergies to active substances. There are currently 14 such CDS.CE checks. The CDS.CE Check thus supports service providers when prescribing new medications or when supplementing existing medication. HCI Solutions is constantly expanding the functionality of Documedis^®. In 2023, the Documedis^® Vaccination module also became available. In the Vaccination module, vaccinations can be documented and checked. The Documedis^® module Primary Care Algorithms (PCA.CE) provides the option of offering precise identification of health disorders and illnesses using algorithms. There are 31 algorithms in total.

In 2024, Galenica was able to further increase patient safety. In the reporting year, 368,813,628 CDS checks¹⁾ were carried out by the service providers, which amounts to an increase of 33% (previous year: 277,609,287). It is realistic to achieve the target by 2025 to 2030.

The satisfaction of our customers is at the heart of all our activities. To measure this, the net promoter score (NPS) of the Amavita, Sun Store and Coop Vitality pharmacies is used and the gap compared to the average of the competition is calculated. The NPS measures the extent to which consumers would recommend a product, a service, a brand or company. Compared to the competition, the ambitious target was not fully achieved at 95.5%¹⁾. For competitive reasons, Galenica does not disclose the actual figure or distance to the best competitor.

¹⁾ ▶ 2024 Data externally assured (limited assurance)

Evaluation of the management approach and measures

• Quality management: The QMS of the Galenica Group companies are regularly and systematically reviewed.
• GDP guidelines: Regional agencies for therapeutic products periodically perform audits to determine GDP compliance.
• Pharmacovigilance: At Verfora, all employees have a duty to submit to the responsible internal department any reports of side effects received from specialists and patients promptly and in full. Information on the duration, progression and impact of the side effect and on the dosage and duration of product use plays a key role in this. Verfora documents and investigates each report, taking appropriate measures where necessary.

Pharmacovigilance: forwarding reports

In 2024, Verfora employees met the deadline for the internal forwarding of reports of side effects in 91% of cases (target: >90%). At Bichsel, the responsible parties met the deadline for forwarding reports of side effects to the authorities in 100% of cases.